Tbxl repressesMef2cgene expression by inducing histone 3 deacetylation of the anterior heart field enhancer

Abstract

The TBX1 gene is haploinsufficient in the 22q11.2 deletion syndrome (22q11.2DS), and genetic evidence from human patients and mouse models points to a major role of this gene in the pathogenesis of this syndrome. Tbx1 can activate and repress transcription and previous work has shown that one of its functions is to negatively modulate cardiomyocyte differentiation. Tbx1 occupies the anterior heart field (AHF) enhancer of the Mef2c gene, which encodes a key cardiac differentiation transcription factor. Here we show that increased dosage of Tbx1 is associated with down regulation of Mef2c expression and reduced acetylation of its AHF enhancer in cultured mouse myoblasts. Consistently, 22q11.2DS-derived and in vitro differentiated induced pluripotent stem cells (hiPSCs) expressed higher levels of Mef2c and showed increased AHF acetylation, compared to hiPSCs from a healthy donor.Furthermore, we show that in mouse embryos, loss of Tbx1 enhances the expression of the Mef2c-AHF-Cre transgene in a regionally restricted and dosage-dependent manner, providing an in vivo correlate of our cell culture data. These results indicate that Tbx1 regulates the Mef2c-AHF enhancer by inducing histone deacetylation.

Right ventricular phenotype, function, and failure: a journey from evolution to clinics

“…A separate enhancer, Foxh1, acting downstream of Isl1, also activates Mefc2 [63]. Additional genes, such as Fgf8, Fgf10, PITX2, and Tbx1, are also preferentially expressed in the anterior heart field where Tbx1 has recently been shown to regulate the Mef2c gene expression [64].…”